These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36337350)

  • 1. The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City.
    Morgan JR; Freibott CE; Jalali A; Jeng PJ; Walley AY; Chatterjee A; Green TC; Nolan ML; Linas BP; Marshall BDL; Murphy SM
    Drug Alcohol Depend Rep; 2022 Sep; 4():. PubMed ID: 36337350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
    Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD
    Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island.
    Zang X; Bessey SE; Krieger MS; Hallowell BD; Koziol JA; Nolen S; Behrends CN; Murphy SM; Walley AY; Linas BP; Schackman BR; Marshall BDL
    JAMA Netw Open; 2022 Nov; 5(11):e2241174. PubMed ID: 36350649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
    Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
    Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy.
    Green TC; Bratberg J; Baird J; Burstein D; Lenz K; Case P; Walley AY; Xuan Z
    Int J Drug Policy; 2020 Nov; 85():102602. PubMed ID: 31740174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naloxone distribution to likely bystanders: Results of an agent-based model.
    Keane C; Egan JE; Hawk M
    Int J Drug Policy; 2018 May; 55():61-69. PubMed ID: 29524734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.
    Rivera AV; Nolan ML; Paone D; Carrillo SA; Braunstein SL
    Subst Abus; 2022; 43(1):1172-1179. PubMed ID: 35617642
    [No Abstract]   [Full Text] [Related]  

  • 10. Projected Estimates of Opioid Mortality After Community-Level Interventions.
    Linas BP; Savinkina A; Madushani RWMA; Wang J; Eftekhari Yazdi G; Chatterjee A; Walley AY; Morgan JR; Epstein RL; Assoumou SA; Murphy SM; Schackman BR; Chrysanthopoulou SA; White LF; Barocas JA
    JAMA Netw Open; 2021 Feb; 4(2):e2037259. PubMed ID: 33587136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
    Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
    Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
    J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.
    Walley AY; Xuan Z; Hackman HH; Quinn E; Doe-Simkins M; Sorensen-Alawad A; Ruiz S; Ozonoff A
    BMJ; 2013 Jan; 346():f174. PubMed ID: 23372174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches.
    Waye KM; Goyer J; Dettor D; Mahoney L; Samuels EA; Yedinak JL; Marshall BDL
    Addict Behav; 2019 Feb; 89():85-91. PubMed ID: 30278306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts.
    Chatterjee A; Yan S; Xuan Z; Waye KM; Lambert AM; Green TC; Stopka TJ; Pollini RA; Morgan JR; Walley AY
    Drug Alcohol Depend; 2022 Jan; 230():109190. PubMed ID: 34864356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts.
    Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Linas BP; Morgan JR; Murphy SM; Walley AY; Schackman BR; Marshall BDL
    Drug Alcohol Depend; 2022 Dec; 241():109668. PubMed ID: 36309001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
    Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
    Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
    Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
    J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.